%0 Journal Article %T Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? %A Velez, Maria A. %A Burns, Timothy F. %J Translational Lung Cancer Research %D 2019 %B 2019 %9 %! Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? %K %X The immune checkpoint inhibitor pembrolizumab, has been shown to be efficacious and to have significant and durable antitumor activity in a subset of patients with advanced non-small cell lung cancer (NSCLC). Most notably in NSCLC with high expression of the programmed death ligand-1 (PD-L1). Similarly, there is abundant data to support the use of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy in patients whose tumors harbor EGFR mutations (1). %U https://tlcr.amegroups.org/article/view/28523 %P S339-S342 %@ 2226-4477